Based on the Palisade Bio Inc stock forecast from 1 analysts, the average analyst target price for Palisade Bio Inc is USD 8.00 over the next 12 months. Palisade Bio Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Palisade Bio Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Palisade Bio Inc’s stock price was USD 0.67. Palisade Bio Inc’s stock price has changed by -1.70% over the past week, -32.54% over the past month and -88.62% over the last year.
No recent analyst target price found for Palisade Bio Inc
No recent average analyst rating found for Palisade Bio Inc
Company Overview Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. Read Less
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently unde...Read More
Frequently Asked Questions About Palisade Bio Inc (PALI) Stock
Based on ratings from 1 analysts Palisade Bio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on PALI's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for PALI is USD 8.00 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 8.
PALI stock's Price/Earning ratio is 0.02.
Our analysis grades PALI stock's Price / Earning ratio at A-. This means that PALI stock's Price/Earning ratio is above 9.999999999999998% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PALI may be undervalued for its sector.
The last closing price of PALI's stock was USD 0.67.
The most recent market capitalization for PALI is USD 3.20M.
Based on targets from 1 analysts, the average taret price for PALI is projected at USD 8.00 over the next 12 months.
This means that PALI's stock price may go up by +1,085.89% over the next 12 months.
We can't find any ETFs which contains Palisade Bio Inc's stock.
As per our most recent records Palisade Bio Inc has 8 Employees.
Palisade Bio Inc's registered address is 7750 El Camino Real, Carlsbad, CA, United States, 92009.
You can get more information about it from Palisade Bio Inc's website at https://www.palisadebio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Palisade Bio Inc (PALI) Stock
Based on ratings from 1 analysts Palisade Bio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on PALI's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for PALI is USD 8.00 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 8.
PALI stock's Price/Earning ratio is 0.02.
Our analysis grades PALI stock's Price / Earning ratio at A-. This means that PALI stock's Price/Earning ratio is above 9.999999999999998% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PALI may be undervalued for its sector.
The last closing price of PALI's stock was USD 0.67.
The most recent market capitalization for PALI is USD 3.20M.
Based on targets from 1 analysts, the average taret price for PALI is projected at USD 8.00 over the next 12 months.
This means that PALI's stock price may go up by +1,085.89% over the next 12 months.
We can't find any ETFs which contains Palisade Bio Inc's stock.
As per our most recent records Palisade Bio Inc has 8 Employees.
Palisade Bio Inc's registered address is 7750 El Camino Real, Carlsbad, CA, United States, 92009.
You can get more information about it from Palisade Bio Inc's website at https://www.palisadebio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PALI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
